Elly R Sherman, Nha Hue Ta, Trisha N Branan, Natt Patimavirujh, Luren Ashton Dickinson, Christopher M Bland, Susan E Smith
{"title":"评估重症患者静脉推注和静脉捎带头孢曲松的疗效。","authors":"Elly R Sherman, Nha Hue Ta, Trisha N Branan, Natt Patimavirujh, Luren Ashton Dickinson, Christopher M Bland, Susan E Smith","doi":"10.3390/antibiotics13100921","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objective</b>: Intravenous fluid shortages have led to fluid-sparing measures such as intravenous push (IVP) administration of antibiotics. This study aimed to compare the safety and efficacy of IVP and intravenous piggyback (IVPB) ceftriaxone in critically ill patients. <b>Results</b>: Demographics were similar in IVP (<i>n</i> = 201) and IVPB (<i>n</i> = 200) groups. Sequential Organ Failure Assessment (SOFA) score was higher, and sepsis and septic shock were more common in the IVP group. Treatment failure occurred in 37.8% of IVP and 19.5% of IVPB groups (<i>p</i> < 0.001). Hospital mortality was more common with IVP (21.4% vs. 9.5%, <i>p</i> < 0.001). Hospital LOS was longer with IVP while intensive care unit (ICU) LOS was similar between the groups. IVP ceftriaxone (OR 2.33, 95% CI 1.43-3.79) and the SOFA score (OR 1.18, 95% CI 1.1-1.27) were associated with treatment failure. <b>Methods</b>: A single-center, retrospective cohort study included adults admitted to an ICU from 2016 to 2021 who received empiric ceftriaxone for ≥72 h. The primary outcome was treatment failure, defined as a composite of inpatient mortality or escalation of antibiotics. Secondary outcomes included length of stay (LOS) and mortality. Chi-squared and independent-sample <i>t</i>-tests were used. Treatment failure was evaluated using multivariate logistic regression. <b>Conclusions</b>: Compared to IVPB, IVP ceftriaxone was associated with higher treatment failure in critically ill patients. Both safety and efficacy should be considered before implementing novel antibiotic administration strategies in practice based primarily on convenience.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"13 10","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504261/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the Efficacy of Intravenous Push and Intravenous Piggyback Ceftriaxone in Critically Ill Patients.\",\"authors\":\"Elly R Sherman, Nha Hue Ta, Trisha N Branan, Natt Patimavirujh, Luren Ashton Dickinson, Christopher M Bland, Susan E Smith\",\"doi\":\"10.3390/antibiotics13100921\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background/Objective</b>: Intravenous fluid shortages have led to fluid-sparing measures such as intravenous push (IVP) administration of antibiotics. This study aimed to compare the safety and efficacy of IVP and intravenous piggyback (IVPB) ceftriaxone in critically ill patients. <b>Results</b>: Demographics were similar in IVP (<i>n</i> = 201) and IVPB (<i>n</i> = 200) groups. Sequential Organ Failure Assessment (SOFA) score was higher, and sepsis and septic shock were more common in the IVP group. Treatment failure occurred in 37.8% of IVP and 19.5% of IVPB groups (<i>p</i> < 0.001). Hospital mortality was more common with IVP (21.4% vs. 9.5%, <i>p</i> < 0.001). Hospital LOS was longer with IVP while intensive care unit (ICU) LOS was similar between the groups. IVP ceftriaxone (OR 2.33, 95% CI 1.43-3.79) and the SOFA score (OR 1.18, 95% CI 1.1-1.27) were associated with treatment failure. <b>Methods</b>: A single-center, retrospective cohort study included adults admitted to an ICU from 2016 to 2021 who received empiric ceftriaxone for ≥72 h. The primary outcome was treatment failure, defined as a composite of inpatient mortality or escalation of antibiotics. Secondary outcomes included length of stay (LOS) and mortality. Chi-squared and independent-sample <i>t</i>-tests were used. Treatment failure was evaluated using multivariate logistic regression. <b>Conclusions</b>: Compared to IVPB, IVP ceftriaxone was associated with higher treatment failure in critically ill patients. Both safety and efficacy should be considered before implementing novel antibiotic administration strategies in practice based primarily on convenience.</p>\",\"PeriodicalId\":54246,\"journal\":{\"name\":\"Antibiotics-Basel\",\"volume\":\"13 10\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504261/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antibiotics-Basel\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/antibiotics13100921\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics13100921","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景/目的:由于静脉输液短缺,人们采取了静脉推注(IVP)抗生素等节约输液的措施。本研究旨在比较重症患者静脉推注和静脉回输头孢曲松的安全性和有效性。研究结果IVP组(n = 201)和IVPB组(n = 200)的人口统计学特征相似。IVP组的序贯器官衰竭评估(SOFA)评分更高,脓毒症和脓毒性休克更常见。IVP组和IVPB组分别有37.8%和19.5%的患者出现治疗失败(P < 0.001)。IVP 组的住院死亡率更高(21.4% 对 9.5%,P < 0.001)。IVP组的住院时间更长,而两组重症监护室(ICU)的住院时间相似。静脉滴注头孢曲松(OR 2.33,95% CI 1.43-3.79)和 SOFA 评分(OR 1.18,95% CI 1.1-1.27)与治疗失败有关。研究方法一项单中心回顾性队列研究纳入了2016年至2021年期间入住ICU并接受经验性头孢曲松治疗≥72小时的成人。次要结果包括住院时间(LOS)和死亡率。采用卡方检验和独立样本 t 检验。采用多变量逻辑回归对治疗失败进行评估。得出结论:与 IVPB 相比,IVP 头孢曲松对重症患者的治疗失败率更高。在主要基于方便性的基础上实施新型抗生素给药策略之前,应同时考虑安全性和有效性。
Evaluation of the Efficacy of Intravenous Push and Intravenous Piggyback Ceftriaxone in Critically Ill Patients.
Background/Objective: Intravenous fluid shortages have led to fluid-sparing measures such as intravenous push (IVP) administration of antibiotics. This study aimed to compare the safety and efficacy of IVP and intravenous piggyback (IVPB) ceftriaxone in critically ill patients. Results: Demographics were similar in IVP (n = 201) and IVPB (n = 200) groups. Sequential Organ Failure Assessment (SOFA) score was higher, and sepsis and septic shock were more common in the IVP group. Treatment failure occurred in 37.8% of IVP and 19.5% of IVPB groups (p < 0.001). Hospital mortality was more common with IVP (21.4% vs. 9.5%, p < 0.001). Hospital LOS was longer with IVP while intensive care unit (ICU) LOS was similar between the groups. IVP ceftriaxone (OR 2.33, 95% CI 1.43-3.79) and the SOFA score (OR 1.18, 95% CI 1.1-1.27) were associated with treatment failure. Methods: A single-center, retrospective cohort study included adults admitted to an ICU from 2016 to 2021 who received empiric ceftriaxone for ≥72 h. The primary outcome was treatment failure, defined as a composite of inpatient mortality or escalation of antibiotics. Secondary outcomes included length of stay (LOS) and mortality. Chi-squared and independent-sample t-tests were used. Treatment failure was evaluated using multivariate logistic regression. Conclusions: Compared to IVPB, IVP ceftriaxone was associated with higher treatment failure in critically ill patients. Both safety and efficacy should be considered before implementing novel antibiotic administration strategies in practice based primarily on convenience.
Antibiotics-BaselPharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
7.30
自引率
14.60%
发文量
1547
审稿时长
11 weeks
期刊介绍:
Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.